| Background Neovascularization and angiogenesis have been considered to be related to the growth, infiltration and metastasis of malignant tumors. Basic fibroblast growth factor(bFGF) is the most important growth factor in the proliferation of the endothelial cells. bFGF is currently considered one of the most essential angiogenic growth factors, not only having important physiologic function, but also playing critical roles in the growth, infiltration and metastasis of malignant tumors. Studies overseas were shown that bFGF was over expressed in acute leukemia(AL). Tumor supplied group of factors(TSGF) consists of glucide, amino acid and other factors related to some kinds of tumor. It is one of the internationally accepted tumor markers, and a significant increase of TSGF level was found in the serum of early cancer. TSGF is widely acknowledged to be of great value in the assistant diagnosis of early cancer, and it has high sensitivity, specificity as a perfect new index for assistant diagnosis of wide-spectrum early cancer. However, the relationship between serum levels of bFGF and TSGF and the occurrence, progression and prognosis of AL has been little reported for domestic study.Objective To determine the serum levels of bFGF and TSGF in patients with AL and to study the relationship between the levels of bFGF and TSGF andthe occurrence, progression and prognosis of AL.Methods 55 patients with AL were chosen, including 31 cases of acute lymphocyte leukemia (ALL), 26 cases of acute myelogenous leukemia(AML). Serum levels of bFGF were measured by enzyme-linked immunosorbent assay(ELISA), Serum levels of TSGF were measured by colorimetric estimation and some other related items were determined as well. To compare the variation of bFGF and TSGF levels of AL patients pretreated and post-treated and to observe the correlation of bFGF, TSGF and other related items. All data were analyzed by SPSS 10.0.Results 1.Comparison of serum bFGF and TSGF between ALL, AML and normal subjects: (1). Serum bFGF levels of ALL were (66.53 ±27.26)pg/L, they were higher obviously than those[(24.06±5.97)pg/L] of normal subjects and the difference was significant(/=6.71, PO.001); serum TSGF levels of ALL were (79.07± 15.38)U/ml, they were higher obviously than those[(51.29± 7.54)U/ml] of normal subjects and the difference was significant(f=6.847, PO.001). (2). Serum bFGF levels of AML were (56.76±21.63)pg/L, they were higher obviously than those[(24.06±5.97)pg/L] of normal subjects and the difference was significant(/=6.18, PO.001); serum TSGF levels of AML were (76.77 ± 14.87)U/ml, they were higher obviously than those[(51.29±7.54)U/ml] of normal subjects and the difference was significant(f=5.009, PO.001). 2. Comparison of serum bFGF and TSGF of ALL, AML pretreated and post-treated: AL were divided into completely remission(CR) group and no completely remission(NR) depended on the reaction on first chemical therapy. (1).Serum bFGF levels of ALL CR group were (58.20 ± 33.49)pg/L and (32.71 ± 15.93)pg/L respectively before and after treatment, and the difference between them was significant(f=3.073, PO.01); Serum bFGF levels of ALL NR group were (86.38 ±22.43)pg/L and (78.52+19.04pg/L)pg/L respectively before and after treatment, and the difference between them was not significant(f=0.651,P>0.05). (2). Serum TSGF levels of ALL CR group were (75.12±15.91)U/ml and (56.37 ± 19.64)U/ml respectively before and after treatment, and the difference between them was significant(f=3.318, P<0.0\); Serum TSGF levels of ALL NR group were (93.51 ± 14.82)U/ml and (81.58 + 17.29)U/ml respectively before and after treatment, and the difference between them was not significant(f=1.283, P>0.05). (3).Serum bFGF levels of AML CR group were (51.93+ 25.62)pg/L and (34.89 + 16.54)pg/L respectively before and after treatment, and the difference between them was significant(f=2.088, P<0.05); Serum bFGF levels of AML NR group were (62.51+ 14.84)pg/L and (56.47 + 18.32)pg/L respectively before and after treatment, and the difference between them was not significant(/=0.651, P>0.05). (4). Serum TSGF levels of AML CR group were (71.90+13.65)U/ml and (54.47 + 17.02)U/ml respectively before and after treatment, and the difference between them was signiflcant(f=2.994, PO.01); Serum TSGF levels of AML NR group were (89.74+16.58)U/ml and (80.06+18.55)U/ml respectively before and after treatment, and the difference between them was not significant^ 1.029, P>0.05). 3. Comparison of serum bFGF and TSGF between CR group and NR group pretreated: (1). In ALL patients, Serum bFGF levels of CR group pretreated were (58.20+ 33.49)pg/L, and those of NR group were (86.38+ 22.43)pg/L, serum bFGF levels of NR group were higher obviously than those of CR group(f=2.43, P<0.05); In ALL patients, Serum TSGF levels of CR group pretreated were (75.12+15.91 )U/ml, and those of NR group were (93.51 ±14.82)U/ml, serum TSGF levels of NR group were higher obviously than those of CR group(f=3.29, PO.05). (2). In AML patients, Serum bFGF levels of CR group pretreated were (51.93 + 25.62)pg/L, and those of NR group were (62.51 ± 14.84)pg/L, and the difference between them was not significant(/=0.76, P>0.05); In AML patients, Serum TSGF levels of CR group pretreated were (71.90+ 13.65)U/ml, and those of NR group were (89.74+ 16.58U/ml)U/ml, serum TSGF levels of NR group werehigher obviously than those of CR group(^2.13, P<0.05). 4. Positive correlation were shown between serum bFGF and TSGF(r=0.5263, P<0.01). 5. No correlations were shown between serum bFGF and bone marrow blasts, serum white blood cell(WBC), platelet(PLT) and hemoglobin(Hb)(r=0.269, 0.247, -0.185, -0.291; P>0.05); no correlations were shown between serum TSGF and bone marrow blasts, serum WBC, PLT and Hb either(r=0.173, 0.209, -0.117, -0.256; P >0.05).Conclusion (1). Serum bFGF and TSGF levels in patients with ALL and AML are higher than those of normal subjects. (2). Serum bFGF and TSGF are useful items for detecting the effect of treatment in ALL and AML. (3). Serum TSGF is a valuable item for evaluation prognosis in both ALL and AML, while significance of bFGF for evaluation prognosis is shown only in ALL. (4). Positive correlation is shown between serum bFGF and TSGF in AL.
|
PDF Full Text Request